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DESCRIPTION OF THE EVIDENCE COLLECTION 
METHODOLOGY
Articles in the MedLine (PubMed) database and other research 
sources were reviewed, with no age limit.
The search strategy used was based on structured questions in 
the P.I.C.O. format (from the initials: Patient, Intervention, Control and 
Outcome). The descriptors used were: Exercise, Physical OR Physical 
Exercise OR Physical Exercises OR prevention and control OR preventive 
therapy OR preventive measures OR prophylaxis OR preventions OR 
control OR Guillain-Barre Syndrome OR Syndrome, Guillain-Barre 
OR Guillaine-Barre Syndrome OR GuillaineBarre Syndrome OR 
Syndrome, GuillainBarre OR Polyneuropathy, Acute Inflammatory 
OR Acute Autoimmune Neuropathy OR Acute Autoimmune 
Neuropathies OR Plasmaphereses OR Plasmapheresis OR Plasma 
Exchange OR Immunoglobulins/therapeutic use OR Immunoglobulins/
administration and dosage OR Exercise Therapy OR Physical Therapy 
OR Physical Therapies OR Exercise therapies OR Resistant Training OR 
Strength Training OR rehabilitation OR Splints OR Splint OR Orthopedic 
Fixation Devices OR Orthotic Devices OR device orthotic OR devices 
orthotic OR Orthoses OR Orthosis OR Upper Extremity OR Upper 
Extremities OR Upper Limb OR Upper limbs OR Membrum Superius 
OR Extremities, Upper OR Limb, Upper OR Limbs, Upper OR hand 
deformities OR Hand Deformities, acquired OR Rehabilitation OR Lower 
Extremity OR Extremities, Lower OR Lower Extremities OR Lower Limb 
OR Limb, Lower OR Lower Limbs OR Membrum Inferius OR Walking 
OR Ambulation OR dependent ambulation OR Ambulation, Dependent 
OR gait OR gaits OR Functional Electrical Stimulation OR Electrical 
Stimulation, Functional OR Fes OR Electric Stimulation Therapy OR 
Stimulation Therapy, Electric OR Therapeutic Electrical Stimulation 
OR Electrical Stimulation, Therapeutic OR Stimulation, Therapeutic 
Electrical OR Therapy, Electric Stimulation OR Therapeutic Electric 
Stimulation OR Electric Stimulation, Therapeutic OR Stimulation, 
Therapeutic Electric OR Electrical Stimulation Therapy OR Stimulation 
Therapy, Electrical OR Therapy, Electrical Stimulation OR Self-help 
devices OR Self-help device OR Device, Self-Help device OR Assistive 
Technology OR Assistive Technologies OR Technologies, Assistive OR 
Technology, Assistive OR Assistive Devices OR Assistive Device OR 
Device, Assistive OR Devices, Assistive OR daily activities OR daily 
activity OR activity of daily living OR activities of daily living OR activities 
of self care OR activity of self care OR usual activities OR usual activity 
OR usual activity of daily living OR usual activities of daily living OR 
Patient Positioning OR Patient Positionings OR Positioning, Patient OR 
Positionings, Patient OR pressure ulcer OR pressure ulcer/prevention 
& control OR Guillain-Barre OR Guillain-Barre Syndrome/therapy* OR 
Guillain-Barre Syndrome/rehabilitation* OR Nursing care OR Pressure 
Ulcer OR Pressure Ulcers OR Pressure Sore OR Pressure Sores OR 
Decubitus ulcer OR Bed sore OR Bedsore OR Weaning Mechanical 
Ventilation OR Extubation OR Mechanical Ventilation Predictors OR 
Weaning Mechanical Ventilator Predictors OR Extubation Predictors.
QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS:
A: Experimental or observational studies of highest quality.
B: Experimental or observational studies of lower quality.
C: Case studies (uncontrolled studies).
D: Opinion with no critical evaluation, based on consensus; physio-
logical studies, or animal models.
OBJECTIVE:
To provide information about the treatment and reabilitation of 
patients with dystonias.
PROCEDURES:
Therapeutic rehabilitation interventions for the main clinical 
manifestations that compromise the quality of life, function, and daily 
life activities of patients with dystonia.
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INTRODUCTION
Guillain-Barré syndrome (GBS) is one of the most frequent sub-
types of acute peripheral polyneuropathy1 (A). It affects 2 people per 
100,000 annually, at random. There is evidence of a higher incidence 
of the disease among males and people aged 50-74 years, however it 
can affect individuals of any sex, age, or race2 (C). From 4% to 15% of 
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patients with GBS die during treatment and approximately 20% are left 
with disability1 (A).
Acute acquired GBS inflammation leads to demyelination of the 
peripheral nerves, then to motor weakness and sensory changes. Its 
cause has not yet been identified, however there has been observed 
in some patients a relationship with acute illness caused by bacteria or 
virus. Among the most common infectious agents which precede GBS 
are found cytomegalovirus, Campylobacter Jejuni, and the Epstein-Barr 
vírus, among others2 (C). Although uncommon, some hepatotrophic 
viruses (hepatitis A, B, C) have been recognized as potential agents for 
the development of GBS3 (D). In such cases GBS usually occurs 1 to 3 
weeks after the infectious event. The clinical course is characterized by 
progressive, symmetrical ascending motor loss (from lower to upper 
extremities) and hyporeflexia or areflexia, with compromising of the 
cranial nerve2 (C). The progression of motor weakness occurs quickly. 
The acute phase begins with the first symptoms and lasts until the 
stabilization of demyelination, which can take days or even weeks. 
After this period begins the recovery phase, which can last for about 
two years and coincides with the regeneration and remyelination 
of axons4 (C). There are two main types of GBS: acute inflammatory 
demyelinating polyneuropathy (AIDP), which affects the myelin 
sheath, and acute motor axonal neuropathy (AMAN), known to be 
purely motor1 (A).
Therapies commonly used to treat GBS in their acute phase 
are plasmapheresis (PE) and intravenous immunoglobulin (IVIg). 
PE consists of performing dialysis in which the patient’s blood is 
processed by a machine that separates and removes antibodies from 
the patient and replaces them with a fluid containing 5% albumin. In 
IVIg treatment, the method considered safer and more widely used, 
an array of antibodies with normal serology is applied intravenously in 
patients with GBS4 (C).
Common symptoms in the acute phase of GBS are: muscle 
weakness, paralysis, numbness, tingling, pain that starts in the legs 
and reaches the entire body, and diminished reflexes. The weakness 
in the trunk and the upper limbs can reach the muscles required for 
respiration and necessitate mechanical ventilation in about 25% of 
cases. Involvement of the autonomic system is frequent and may cause 
urine retention, tachycardia, hypertension, orthostatic hypotension 
and cardiac arrhythmia1 (A). Other complications associated with 
the acute phase of Guillain-Barré syndrome are insomnia, formation 
of pressure sores, difficulty communicating, nutritional deficiency, 
immobility, and venous thrombosis2 (C).
Studies show that treatment of GBS should be performed by 
a multidisciplinary team, providing symptom management and 
prevention of complications during the acute phase of the disease1 (A). 
Physical rehabilitation is required in 40% of GBS cases; action by the 
interdisciplinary team is essential to minimize consequences and 
promote the independence and autonomy of patients5 (D).
1. Which strategy is most effective in the treatment of 
acute-phase Guillain-Barré syndrome, treatment with 
plasmapheresis (PE) or administration of intravenous 
immunoglobulin (IVIG)?
When plasmapheresis (PE) is used in 5 sessions of plasma exchange 
of 50 ml/kg in an adult population with Guillain-Barré syndrome 
(GBS) without pre-existing disease, results are similar to intravenous 
immunoglobulin therapy (IVIg) with 0.4 g/kg of human immunoglobulin 
for 5 days. There are no statistical differences in the results of the two 
therapies, either in the improvement in degree of disability during a 
4 week period and the pattern of functional recovery, or the time to 
recovery of independent walking (average days to return to walking 
without support was 49 days for patients who underwent PE and 51 
days for patients who were treated with IVIg). The time required to 
discontinue mechanical ventilation in patients who need this type of 
resource is also similar (average of 29 days for individuals treated with 
PE compared with 26 days for those undergoing IVIg). The number 
of deaths during both therapies is comparable, about 1.7% among 
those who underwent PE and 2.3% for patients treated with IVIg (with 
Relative Risk Reduction (RRR) -35%, Absolute Risk Reduction (ARR) 
-0.006, and Confidence Interval (CI) 95%).
Complications that can be observed with the use of PE are: 
hypotension, sepsis, pneumonia, malaise, abnormal clotting, 
hypocalcemia. During the application of IVIg, náusea, vomiting, 
meningism, deteriorating renal function, myocardial infarction and 
possible painful erythema in the region of the infusion may occur. The 
combination of PE followed by IVIg (5 sessions of plasma exchange, 
50 ml/kg, followed by 5 daily applications of 0.4 g/kg of Sandoglobulin 
starting soon after the last day of PE), also shows results similar to 
those cited above6 (A).
The application of IVIg at a dosage of 0.5 g/kg in 4 daily doses when 
compared with PE therapy (200 to 250 ml/kg in 5 sessions distributed 
in a 7-10 day interval using the techniques of centrifugation or cell 
membrane separation) also shows similar results in motor function 
recovery 1 month from the beginning of treatment. The average time 
to improvement of a degree of motor function using a specific disability 
grade scale shows little difference in favor of the use of the PE (16.5 days 
to 14.0 days when using IVIg); patients treated with PE have on average 
1 point more than those undergoing IVIg. Regarding complications 
related to both therapies it is possible to observe: hypotension, cardiac 
arrhythmia, pneumonia, deep vein thrombosis/pulmonary embolism, 
sepsis, local phlebitis and infections of the urinary tract. There is a 
tendency for a lower incidence of these complications in favor of IVIg 
(p = 0.07)7 (B).
When comparing PE (200 to 250 ml/kg in 5 sessions conducted 
between 7 to 14 days with replacement fluid containing 5% albumin 
and no IgG, using two management techniques: centrifugation, 
and ultrafiltration) and the application of IVIg (5 daily sessions of 
0.4 ml/kg), there are favorable results using IVIg: improved levels 
of functional capacity during the first 4 weeks following initiation of 
treatment, about 53% of those treated with IVIg compared to 34% of 
patients who underwent PE, with p = 0.024. The average number of 
days required to restore independent walking is also favorable for IVIg 
therapy, 55 days versus 69 days for PE, with p = 0.07. The complications 
observed most in both groups are: pneumonia, atelectasis, thrombosis 
and hemodynamic changes. There are a greater number of such events 
in patients treated with PE, similarly, a greater proportion of subjects 
required mechanical ventilation in this population (48% PE versus 27% 
of patients treated with IVIg, p < 0.05)8 (A).
With GBS patients for whom PE is contraindicated (due to 
uncontrolled sepsis, severe changes in homeostasis, hemodynamic 
instability), the use of IVIg at a dose of 0.4 g/kg for 12 hours daily for a 
6 day period is shown to be more effective than the same dose of IVIg 
administered for 3 days. PE has the lowest average number of days to 
recover walking function (84 days to walking with assistance, compared 
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to 131 days for patients treated with IVIg for 3 days, and 97 versus 
152 days on average to achieve independent walking, respectively 
p = 0.39). This positive tendency in the application of IVIg for six days 
also occurs when evaluating the functional improvement in a 4 week 
period using a specific scale for measuring function in Guillain-Barré 
syndrome (44% versus 22%, p = 0.27)9 (A).
Recommendation
Efficacy is similar with the application of plasmapheresis 
therapy (PE) in 5 daily sessions of plasma exchange of 50 ml/kg, 
and intravenous immunoglobulin (IVIg) therapy at a dose of 0.4 
g/kg human immunoglobulin for 5 days, in adult patients with 
Guillain-Barré syndrome (GBS) without pre-existing illness or 
conditions contraindicating the procedures. This relates to functional 
improvement in 4 weeks, the time to recovery of independent 
walking, mortality rate, and the duration of mechanical ventilation 
in patients who require this resource. The combination of PE and 
IVIg (5 sessions of plasma exchange, 50 ml/kg, followed by 5 daily 
applications of 0.4 g/kg of Sandoglobulin starting soon after the last 
day of PE) brings no greater benefits than treatment with PE or IVIg 
alone6 (A).
The results remain similar between plasmapheresis and IVIg 
when using the following dosages: 200-250 ml/kg in 5 sessions 
distributed over a 7 to 10 day interval, using the techniques of 
separation or centrifugation of the cell membrane and 4 doses of 
0.5 g/kg for 4 consecutive days, respectively. However, IVIg has shown 
to be slightly safer compared to PE with regard to complications 
during treatment7 (B).
However, IVIg therapy (administration of 0.4 ml/kg in 5 
daily sessions) is more effective than treatment with PE (200 to 
250 ml/kg in 5 sessions conducted between 7 to 14 days, with fluid 
containing 5% albumin and no IgG, prepared using ultrafiltration 
and centrifugation techniques), with respect to functional recovery 
during a 4-week period, and the safety of treatment due to fewer 
complications and less need for mechanical ventilation8 (A).
For patients who have contraindications to PE due to 
uncontrolled sepsis, severe alterations of homeostasis, or 
hemodynamic instability, therapy with IVIg (0.4 g/kg over 12 hours, 
daily, for 6 days) is effective and has better results both for 
functional recovery in 4 weeks and for independent walking than 
the same protocol lowered to 3 days of application. The occurrence 
of adverse reactions are similar in the two forms of treatment9 (A).
2. Which techniques for stimulating active movement and 
strengthening are indicated for improved function 
and decreasing long-term disability in patients with 
Guillain-Barré syndrome?
Results from low and high intensity physical rehabilitation 
programs were compared. Patients were adults with Guillain-Barré 
syndrome (GBS) considered chronic, with more than three 
years since onset of acute symptom diagnosis, and who had not 
participated in rehabilitative activity within the previous 24 months. 
The high intensity program was developed on an individualized 
basis following clinical assessment, consisting of one-hour sessions 
up to 3 times per week. The sessions were conducted over 12 
weeks, organized in 30-minute blocks of occupational therapy, 
physiotherapy, psychology and speech-language pathology. 
Physiotherapy worked on strengthening, endurance and gait 
training, and occupational therapy sought to improve performance 
in ADL, driving and work. For the low-intensity programs, 
home-based consults were developed, with maintenance exercises 
(walking and stretching) and education for self-care in 30-minute 
sessions twice a week. To analyze the results obtained with this 
intervention the following scales were used: FIM (Functional 
Independence Measure), World Health Organization Quality of Life 
(WHOQoL-BREF), Depression, Anxiety, and Stress Scale (DASS), and 
the PIPP tool (Perceived Impact of Problem Profile (PIPP)10 (A).
After 12 weeks of treatment, 68.6% of patients who received 
the high intensity rehabilitation program showed functional 
improvement, versus 32.4% in the low intensity group. A larger 
number of subjects reported deterioration of function in the group 
that underwent the low intensity program (41.2%, versus 2.9% of 
the patients who received the intensive rehabilitation treatment, 
p < 0.001). Of the patients in the latter group, 80% improved 3 
points on the FIM scale compared to 8% of the individuals in the low 
intensity program. In the areas of self-care and mobility, the high 
intensity treatment group showed improvement of 54.8% and 41.9% 
respectively, (versus 5.3% and 2.6% in the low intensity group). This 
positive difference for individuals in the more intense program of 
rehabilitation was also perceived, although to a milder degree, in the 
skills of walking and bowel control10 (A).
There was no significant change in the scores derived from the 
application of the DASS, WHO-QoL and PIPP in both groups, except 
for the subscale of relationships in the PIPP10 (A).
Recommendation
In adult patients with chronic Guillain-Barré syndrome (GBS) with 
more than 3 years elapsed since onset of acute phase symptoms, and 
with no participation in rehabilitative activity within the previous 
24 months, the development of a multidisciplinary rehabilitation 
program promotes improved motor function and performance 
of Activities of Daily Living, increases scores of Functional 
Independence Measure (FIM), and prevents the deterioration of 
functional capacity. This program consists of sessions of occupational 
therapy (performance improvement in the ADL, driving and work), 
physiotherapy (strengthening, muscle endurance and gait training), 
psychology and speech-language pathology. These sessions should 
be scheduled 2 to 3 times per week in blocks of 2 sessions per day, 
30 minutes per session for 12 weeks10 (A).
3. Does the use of orthoses for positioning wrist and 
fingers in patients with Guillain-Barré syndrome prevent 
deformity and contribute to improved function?
Orthoses, by definition, are devices used in the upper limbs (UL) 
and lower limbs (LL) that exert external forces to that segment. They 
may have the goal of stabilizing and/or promoting rest for anatomical 
structures, maintaining bone alignment, preventing deformities and 
contractures, preventing unwanted movement, increasing range of 
motion, promoting stretching in muscle and the soft tissues of the 
musculoskeletal system, replacing the function of lost or damaged 
muscle, relieving pain, restoring function and/or assisting in the 
management of healing {or trauma, or injury}. Thus orthotics can 
help treat orthopedic, neurological, and rheumatological patients, 
among others. In practice, orthoses available to the public may 
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be prefabricated of high temperature thermoformable materials, 
or tailor-made, usually from thermoplastic molded at low 
temperatures11 (D).
There is no specific type of orthesis to be used, but their end 
purpose is the same in acute phase Guillain-Barré syndrome: to 
promote neutral joint positioning as a preventive and/or corrective 
measure to muscle contractures for the ankle and foot or the wrist 
and fingers. This approach seeks to reduce the consequences of loss 
of muscle strength inherent in Guillain-Barré syndrome and promote 
the adequate maintenance of structures to optimize patient 
rehabilitation12 (D).
Recommendation
There is no evidence to certify the use of ortheses in upper 
limbs of patients with Guillain-Barré syndrome (GBS). This resource, 
by placing the joint in a neutral position, helps prevent deformities 
and/or muscle shortening in order to optimize the process of 
rehabilitation, since GBS patients commonly remain confined to bed 
for weeks and have significant symptomatic loss of muscle strength. 
Undoubtedly, there is a need to develop studies that provide further 
evidence for recommending orthoses in this population11,12 (D).
4. Do lower limb orthoses for Guillain-Barré syndrome 
patients aid in walking and contribute to improved 
function?
The use of ortheses to stabilize the foot and ankle in patients 
who present “foot drop” symptoms aims to improve the function 
of the musculoskeletal system. This is a common condition for 
patients with Guillain-Barré syndrome (GBS) which can be enhanced 
with the use of orthesis to provide dorsiflexion support, externally 
applied to the ankle and foot, improving gait function13 (D). The 
use of orthosis is aimed at maintaining foot and ankle articulation 
in a neutral position, ensuring the prevention and/or correction of 
muscle contractures and deformities12 (D).
Recommendation
There are no studies that provide scientific evidence to support 
the practice of indicating lower limb ortheses for patients with 
Guillain-Barré syndrome during rehabilitation programs. In the patient 
population with GBS, gait function is impaired by the presence of 
motor weakness in the lower limbs and the presence of “foot drop” 
is a common symptom. Use of ortheses applied externally to the foot 
and ankle in a manner that promotes dorsiflexion shows benefits like 
improved gait function, prevention and/or correction of contractures 
and deformities, as well as increased independence12,13 (D).
5. Does use of assistive and adaptive technology improve 
functional performance in patients with Guillain-Barré 
syndrome?
Assistive technology is characterized by engaging resources, 
strategies, methodologies, and practices to promote the functional 
capacity and participation of people with disabilities seeking 
autonomy, quality of life and social inclusion. It includes both the 
physical technology, i.e. the object and the equipment itself, as 
well as the theoretical technology or knowledge that is required 
to evaluate, create, select and prescribe these devices. Adaptive 
and assistive equipment are classified in different categories: the 
Activities of Daily Living, Alternative Communication Systems, 
Environmental Control Units, Home Environment, Computers, 
Wheelchairs & Mobility Devices, and Vehicle Adaptations, among 
others14 (D).
To the extent that patients with Guillain-Barré syndrome undergo 
a period of motor weakness that can range from weeks to months, 
with hyporeflexia or areflexia, they experience disability in different 
areas of daily life. About 20% of this population will have some type 
of disability one year after disease onset, and even with those who 
have a good recovery of motor function during this period residual 
weakness and muscle fatigue is common1 (A).
Recommendation
There is no scientific evidence that the use of assistive and 
adaptive technologies can improve functional performance of 
patients with Guillain-Barré syndrome (GBS). However, recognizing 
that patients with GBS experience incapacity in several areas of 
their lives and that a percentage of subjects will be left with some 
type of disability, the use of adaptive and assistive technology can 
contribute to greater independence, autonomy and social inclusion 
for this patient population14 (D). We emphasize the importance of 
further scientific studies in this area.
6. Are stretching and passive mobilization approaches 
effective for the prevention of contracture and 
promoting functional improvement in patients with 
acute-phase Guillain-Barré syndrome?
Patients with Guillain Barré syndrome (GBS) in its acute phase 
experience a prolonged period of immobilization that can cause 
complications and impair patient recovery and rehabilitation. 
Among the symptoms that can manifest during this acute phase of 
the illness and hospitalization are postural hypotension, increased 
levels of serum calcium, pressure ulcers, compression of nerves, and 
heterotopic calcification with an increase in the level of calcium. Early 
mobilization of the patient allows serum calcium levels to decrease 
and prevents hypercalcemia caused by immobility5 (C).
The immobility experienced by GBS patients due to paralysis and 
muscle weakness also puts them at risk for developing deep vein 
thrombosis. Among the preventive treatments, passive mobilization 
has been used to reduce the incidence of deep venous thrombosis 
in this population. Regular physiotherapy, including passive 
mobilization exercises, also helps in preventing contractures and, 
coupled with isometric and isotonic exercises, promotes a reduction 
in loss of muscle strength in patients with acute-phase GBS2 (C).
There are few studies showing scientific evidence to support the 
practices and methods in the area of multidisciplinary rehabilitation. 
The studies are more oriented toward individual and institutional 
experiences. However, rehabilitation has shown to be as important 
as pharmacological medical treatment1 (A).
Recommendation
There is little scientific evidence to indicate the use and certify 
the benefits of stretching exercises and passive mobilization in 
patients with Guillain-Barré syndrome during its acute phase, 
whether to prevent deformities or to improve motor function. 
However, in practice, the approach of early passive joint mobilization 
with isometric and isotonic exercises helps both in the prevention 
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of contractures and deformities, such as complications related 
to immobility and loss of strength, and maintenance of muscle 
trophism. Developing studies with greater scientific evidence is 
necessary1,2,5 (C).
7. Is the use of carbamazepine and gabapentin indicated 
for the management of pain in patients with acute-phase 
Guillain-Barré syndrome? Is there a better result with 
one drug compared to the other?
Carbamazepine (3 days of treatment, 100 mg every 8 hours 
through the feeding tube) was compared to placebo in controlling 
pain in patients in the recovery phase of Guillain-Barré syndrome 
(GBS) under mechanical ventilation in the Intensive Care Unit. At the 
end of therapy, a moderate reduction in the need for analgesic use of 
intravenous pethidine (0.5-1 mg/kg) was obtained, with an average 
consumption of 1.1 ± 1.0 mg/kg/day during use of carbamazepine, 
versus 3.7 ± 0.9 mg/kg/day of individuals who received placebo, 
with p < 0.001. Scoring pain on a scale (0-10, ten being the worst 
pain level), there is a perceptible decrease in pain intensity over the 
period of use with carbamazepine, 1.7 ± 0.8, compared to the use 
of placebo 3.1 ± 0.9, p < 0.001. The score for sedation of patients on 
carbamazepine was also better compared to the placebo, 2.3 ± 0.9 
versus 4.2 ± 0.9 respectively, p < 0.001. There were no significant 
side effects observed. Supportive therapies were continued during 
treatment with carbamazepine, such as enteral nutrition, antibiotic 
coverage to prevent infections, respiratory physiotherapy, motor 
physical therapy, protecting the digestive tract, venous thrombosis 
prophylaxis, sedation overnight to maintain sleep patterns15 (A).
The use of gabapentin in 3 divided doses of 15 mg/kg/day for 7 
days dissolved in 5 ml of water and administered through Ryle tube 
was able to reduce the average pain score from 7.22 ± 0.83 at baseline 
to 06.02 ± 0.63, p < 0.001, compared to placebo. Although there was 
also a decrease in this score when using placebo, it was not significant. 
The need for analgesic, evaluated from the amount consumed, also 
significantly decreased during application of gabapentin, dropping 
from 211.11 ± 21.38 (μg) on the first day to 65.55 ± 16.17 (μg) at the 
end of the treatment period, with p < 0.001. With placebo, there 
was no significant change in analgesic consumption, 319.44 ± 25.08 
(µg) on the first day and 316.67 ± 24.25 (µg) at the end of 7 days. 
Patients undergoing application of gabapentin, on average, went 
from the level of anxious and agitated to oriented and cooperative 
or responding to commands on the Ramsay Scale of sedation level 
(1.38 ± 0.5 to 0.5 ± 2:44 at the end of treatment). However with the 
placebo, the subjects passed from a state of agitation to decreased 
consciousness, a fall of 1.44 ± 0.51 to 3.63 ± 0.5 on the Ramsay Scale. 
Few side effects were reported with the use of gabapentin compared 
to the application of placebo, suggesting a causal relationship with 
fentanyl, which was used in higher doses as a rescue analgesic in 
the placebo subjects, and was probably responsible for nausea and 
constipation in these patients16 (A).
Comparison of the results of the use of carbamazepine in 3 
daily doses of 100 mg for 1 week and gabapentin 300 mg in 3 daily 
doses for 7 days (dissolved in 10 mL of water delivered through 
Ryle tube), with a control group that used placebo showed: 
significant reduction in the average score on the numeric pain scale 
(where 10 is the maximum intensity of pain) from 8.0 to 2.0 with 
the use of gabapentin, and from 8.0 to 3.0 with carbamazepine, 
with p < 0.05, while the control group was reduced from 8.0 to 
6.0 with no statistical significance. Regarding the average Ramsay 
Score for sedation level, the use of gabapentin and carbamazepine 
provided lower rates of sedation compared to the placebo group, 
with p < 0.05, with final averages of (2.0, 3.0, 4.0, respectively). As 
for average daily need for application of analgesic, use of fentanyl 
IV (2μg) decreased both with the use of the medications and with 
placebo. However, at the end of treatment a higher average daily 
amount of analgesic was used in patients who received placebo 
(350.7 ± 34.2) p < 0.05 compared to the groups on gabapentin, 
126.0 ± 26.2 and carbamazepine 174.5 ± 30.0. The patients showed 
no side effects during treatment17 (A).
Recommendation
The use of carbamazepine (100 mg every 8 hours administered 
by enteral feeding dissolved in 10 mL of water) and the use of the 
anticonvulsant gabapentin (3 divided doses of 15 mg/kg/day for 
7 days administered via Ryle tube dissolved in 5 mL of water) are 
effective in the treatment of pain in adult patients with Guillain-Barré 
syndrome in ICU making use of mechanical ventilation. Both are 
effective in reducing the average intensity of pain and the use of 
analgesics, and also improve the level of sedation15,16 (A). In addition, 
gabapentin applied in a dosage of 300 mg 3 times daily for one week 
proves more effective in comparison to carbamazepine, 100 mg in 3 
daily doses during the same period (each dissolved in 10 mL of water 
delivered through Ryle tube), not only reducing pain intensity on a 
numeric scale, but also the need for analgesic medication use, as 
well as improving sedation levels in these patients17 (A).
8. Is changing decubitus position of the Guillain-Barré 
syndrome patient during the acute phase effective in 
preventing development of pressure ulcers?
The patient with Guillain-Barré syndrome (GBS), during the 
acute phase of the disease experiences progressive motor weakness, 
mostly with an ascending and symmetrical pattern. Among the 
symptoms are: muscle weakness, numbness, tingling and pain. As 
a consequence of partial or complete paralysis and a state of poor 
nutrition (due to complications that affect the feeding of individuals 
in this situation, such as dysphagia and loss of active movement), 
the skin integrity of these patients becomes quite vulnerable to 
injury. Among the measures employed to maintain the integrity 
of the skin, the following are indicated: frequently changing 
decubitus and positioning (every 30 minutes), applying lotions on 
bony prominences, massage, performing movement and passive 
exercises, as well as maintaining the patient’s skin dry and using 
sheets without wrinkles. Air mattresses, special beds, and pillows 
for heels and elbows are also useful to prevent the formation of 
pressure ulcers2 (C).
It is necessary to involve the interaction of different professionals 
on the team to prevent the formation of pressure ulcers in the 
acute phase of GBS. Frequent change of decubitus added to the 
assessment of skin condition is recommended, as well as passive 
motion exercises performed by therapists or by caregivers18 (C).
It is also necessary from the outset of treatment and 
hospitalization to encourage the patient to change his position 
frequently. When immobility is present, it is necessary to train family 
members and caregivers on how to perform these maneuvers for 
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postural changes of the patient. A schedule of posture changes may 
be placed near the bed in view of the patient and family to facilitate 
their execution. Special beds can also help prevent ulcers19 (C).
Recommendation
The frequent change of decubitus, every 30 minutes, is indicated 
as the primary method to prevent the formation of pressure ulcers in 
patients with Guillain-Barré2,18 (C). However, more scientific studies 
are needed with greater evidence to evaluate and prove the utility 
of position change in this population, as well as to verify the use 
of equipment and other resources for prevention and treatment of 
skin ulcers, such as special beds, the use of specific skin hydrating 
creams, massage, air mattresses and pillows2,19 (C).
9. What are the predictive factors for the need of mechanical 
ventilation and success in the weaning process in 
Guillain-Barré patients?
To predict and assess the need to use mechanical ventilation 
support for prolonged periods in patients with Guillain-Barré 
syndrome (GBS) with acute respiratory failure, it was observed that 
of 61 individuals admitted to the Intensive Care Unit (ICU) from 1996 
to 2009, 65.57% of the patients required mechanical ventilation 
with an average duration of 24 days. Of these, 70% underwent 
tracheostomy, with an average of 14 days between tracheal 
intubation and tracheostomy procedure. Patients who underwent 
mechanical ventilation had higher scores on specific tests of disease 
severity (Simplified Acute Physiologic Score II-SAPS II) compared 
to those who did not need it, scoring 28.2 ± 18.6 and 14.1 ± 6.8 
respectively, p = 0.0052. The glycemic index was significantly higher 
among those who required respiratory support, 8.07 on average 
versus 6.51 mmol/L, p < 0.01. About 60% of mechanically ventilated 
patients showed autonomic dysfunction compared with 14% of those 
non-ventilated, p = 0.0006. Through a multiple logistic regression 
model, it was found that the risk of needing mechanical ventilation 
increased significantly when the individual with GBS exhibited at 
least one sign of cardiovascular autonomic dysfunction and inability 
to actively raise the head when lying down (odds ratio 10.66, 95% 
confidence interval [CI] 2.4 to 49, p < 0.05, and 9.86, 95% CI 1.7 to 
56, p < 0.05, respectively)20 (B).
Regarding factors that may help determine the need for prolonged 
mechanical ventilation, there was a lower rate of vital capacity (VC) 
between those who required ventilatory support for more than 
15 days on admission to the ICU, 46% versus 63% among patients 
with a ventilation period < 15 days, p < 0.01. The plasma sodium 
concentration was found to be significantly decreased in patients 
ventilated for longer than 15 days (p < 0.05), and the ability to flex 
the foot was frequently absent in these subjects, 64.2% versus 33.3% 
of patients who required ventilation for a shorter period p < 0.004. 
This difference remained after the application of immunotherapy 
82.1% compared to 41.6%, respectively, p = 0.001. With the end 
of immunotherapy treatment differences were observed in the 
presence of nerve conduction block also. By analyzing these data, 
it was determined that the combination of lack of standing flexion 
at admission to ICU and at the end of immunotherapy treatment, 
with the presence of sciatic nerve motor conduction block with a 
sensitivity of 56%, has a positive predictive value of 100% for the 
need for greater duration of mechanical ventilation, p < 0.00120 (B).
As to the factors that predict the success of weaning from 
intubation in this population, 44 patients with GBS undergoing 
mechanical ventilation with assisted or intermittent control were 
evaluated. Of these, 31.8% underwent successful extubation, in 13.6% 
weaning failed and 45.5% of the subjects underwent tracheotomy 
without weaning trials. There was no significant difference between 
patients who had successful extubation and the others in relation 
to demographic and clinical characteristics. The hospitalization time 
was longer among patients whose weaning failed or who underwent 
tracheostomy (21.5 ± 11.1 days vs. 12.5 ± 8.7 days in subjects with 
successful extubation, p = 0.005). In the patient group analyzed, the 
following factors demonstrate power in predicting and facilitating 
the evaluation of the optimal time for weaning from mechanical 
ventilation: on the day of weaning from intubation, a VC (Vital Capacity) 
index equal to or greater than 20 ml/kg (with 70% positive predictive 
value for successful extubation), the reduction of negative inspiratory 
force reaching approximately -50.0 cm H
2
O, the improvement in 
CV such that it reaches the previous index measured at the time of 
intubation or increases 4 ml/Kg between the time of pre-intubation 
and extubation, and the absence of pulmonary comorbidities. 
Although it has not shown statistical significance, another factor that 
should also be considered in both intubation and in the weaning 
process is the presence of autonomic dysfunction21 (B).
Recommendation
The presence of at least one sign of cardiovascular autonomic 
dysfunction and the inability to actively raise the head when 
lying down are predictors of mechanical ventilation in patients 
with Guillain-Barré syndrome (odds ratio 10.66, 95% confidence 
interval [CI] 2.4 to 49, p < 0.05 and 9.86, 95% CI 1.7 to 56, p < 0.05, 
respectively20 (B). To predict the need for mechanical ventilation 
over a prolonged period, it is recommended that the combination of 
the absence of standing flexion on admission to ICU and at the end 
of immunotherapy treatment, with the presence of sciatic nerve 
conduction block (with sensitivity of 56%, positive predictive value of 
100%, p < 0.001) be considered20 (B). With respect to weaning from 
intubation, it is important to consider a Vital Capacity (VC) index equal 
to or greater than 20 ml/kg at the time of the procedure, reduced 
negative inspiratory force reaching approximately -50.0 cm H
2
O, the 
improvement in CV such that it reaches the index measured previous 
to intubation, or increases 4 ml/Kg between the time of pre-intubation 
and extubation and/or the absence of pulmonary co-morbidities21 (B).
10. Is the application of functional electrical stimulation 
(fes) in upper or lower limbs indicated to promote 
active movement and increase strength in patients with 
Guillain-Barré syndrome?
There are no articles that address the use of the application 
of Functional Electrical Stimulation (FES) in the population with 
Guillain-Barré syndrome or acute polyneuropathies, during rehabi-
litation and functional recovery.
Recommendation
There is no evidence to support the use of Functional Electrical 
Stimulation (FES) applied to higher or lower limb muscles in patients 
with Guillain-Barré syndrome. FES is a widely used resource in 
the rehabilitation of patients with neurological injuries, thus it is 
necessary to develop studies in this area (D).
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